Fig. 2
Progression-free survival (PFS) (A) and overall survival (OS) (B) were significantly longer for patients treated with EGFR-TKI with bevacizumab (A+T) than EGFR-TKI monotherapy (T-single)
Fig. 2 | BMC Medicine
Progression-free survival (PFS) (A) and overall survival (OS) (B) were significantly longer for patients treated with EGFR-TKI with bevacizumab (A+T) than EGFR-TKI monotherapy (T-single)